Inovio stockholders elect eight directors, approve omnibus plan at annual meeting

INOVIO PHARMACEUTICALS, INC.

All eight director nominees elected; votes for ranged from 22.3M to 22.7M, with 17.1M broker non-votes.
Ratification of Ernst & Young as auditor for 2026 approved: 39.3M for, 1.2M against, 143k abstain.
Non-binding advisory vote on NEO compensation passed with 21.5M for, 1.6M against, 471k abstain.
Amendment and restatement of 2023 Omnibus Incentive Plan approved with 21.6M for, 1.5M against.
Board adopted bylaw amendment establishing Lead Independent Director role and clarifying Chairman duties.

item 5.03item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.